Case Study #2 – Indication Sequencing to Drive Post-Launch Success
The company is undergoing rapid employee expansion, has a soaring stock price, and must meet investor expectations post-launch. The lead asset was transitioning to Phase III, and was seeking two rare disease indications. Each indication had a similar level of unmet need, but differed in terms of the clinical data, epidemiology, and price potential.
The P4A team and client worked on numerous strategic and tactical activities over a 36-month period involving the clinical development plan, medical affairs support and implementation, pricing and market access, and board level initiatives. To accomplish this plethora of objectives, the P4A team immediately assembled an expert panel of seasoned professionals to guide clinical project / commercial activity prioritization, implemented and managed external engagements, and worked on a daily basis with senior organizational contacts to guide internal decisions based on project results.
Key Client Benefit:
The indication sequence was prioritized to position the lead candidate with the greatest value opportunity, which subsequently secured a highly favorable price and access position in the US, and throughout Europe. The company continues to exceed revenue targets, and is efficiently expanding global operations to meet increasing clinical demand.
The choice to go with a specialised orphan consultancy has paid off. The quality of service and advice we’ve been given has made our launch journey much easier to manage. We made the right choice with the P4A team!
European Business Unit Director